Literature DB >> 28599499

Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlight.

Sandra Pierredon1, Pascale Ribaux1, Jean-Christophe Tille2, Patrick Petignat1, Marie Cohen1.   

Abstract

Ovarian cancer is one of the most common types of reproductive cancer, and has the highest mortality rate amongst gynecological cancer subtypes. The majority of ovarian cancers are diagnosed at an advanced stage, resulting in a five-year survival rate of ~30%. Early diagnosis of ovarian cancer has improved the five-year survival rate to ≥90%, thus the current imperative requirement is to identify biomarkers that would allow the early detection, diagnosis and monitoring of the progression of the disease, or of novel targets for therapy. In the present study, secreted proteins from purified ovarian control, benign and cancer cells were investigated by mass spectrometry, in order to identify novel specific markers that are easy to quantify in patients sera. A total of nine proteins revealed significant differential secretion from control and benign cells, in comparison with ovarian cancer cells. The mRNA expression levels of three of these proteins (Dickkopf protein 3, heat shock protein 10 kDa and gelsolin) were subsequently evaluated by reverse transcription-quantitative polymerase chain reaction. Combined with the protein level in serum, the present study identified that gelsolin may be a useful marker of ovarian cancer.

Entities:  

Keywords:  gelsolin; marker; ovarian cancer; secretome; target

Year:  2017        PMID: 28599499      PMCID: PMC5453169          DOI: 10.3892/ol.2017.6096

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

1.  Comparative analysis of secreted proteins from normal and preeclamptic trophoblastic cells using proteomic approaches.

Authors:  M Epiney; P Ribaux; P Arboit; O Irion; M Cohen
Journal:  J Proteomics       Date:  2011-12-30       Impact factor: 4.044

Review 2.  Targeting the Wnt pathway in cancer: the emerging role of Dickkopf-3.

Authors:  Jürgen Veeck; Edgar Dahl
Journal:  Biochim Biophys Acta       Date:  2011-09-22

3.  Comparative proteomics of ovarian epithelial tumors.

Authors:  Hee Jung An; Dong Su Kim; Yong Kyu Park; Sei Kwang Kim; Yoon Pyo Choi; Suki Kang; Boxiao Ding; Nam Hoon Cho
Journal:  J Proteome Res       Date:  2006-05       Impact factor: 4.466

4.  HSP-10 in ovarian cancer: expression and suppression of T-cell signaling.

Authors:  Sibel Akyol; Cicek Gercel-Taylor; Lisa C Reynolds; Douglas D Taylor
Journal:  Gynecol Oncol       Date:  2006-01-04       Impact factor: 5.482

5.  Loss of Gelsolin expression in human ovarian carcinomas.

Authors:  Aurelia Noske; Carsten Denkert; Hagen Schober; Christine Sers; Bakhyt Zhumabayeva; Wilko Weichert; Manfred Dietel; Kai Wiechen
Journal:  Eur J Cancer       Date:  2005-02       Impact factor: 9.162

6.  Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma.

Authors:  Xiu-Qin Li; Shu-Lan Zhang; Zhen Cai; Yuan Zhou; Tian-Min Ye; Jen-Fu Chiu
Journal:  Cancer Lett       Date:  2008-12-03       Impact factor: 8.679

7.  Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.

Authors:  David Jackson; Rachel A Craven; Richard C Hutson; Ina Graze; Paul Lueth; Robert P Tonge; Joanne L Hartley; Janice A Nickson; Steve J Rayner; Colin Johnston; Benjamin Dieplinger; Michael Hubalek; Nafisa Wilkinson; Timothy J Perren; Sean Kehoe; Geoffrey D Hall; Guenter Daxenbichler; Hans Dieplinger; Peter J Selby; Rosamonde E Banks
Journal:  Clin Cancer Res       Date:  2007-12-15       Impact factor: 12.531

8.  Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas.

Authors:  Bernard Têtu; Ion Popa; Isabelle Bairati; Sylvain L'Esperance; Magdalena Bachvarova; Marie Plante; François Harel; Dimcho Bachvarov
Journal:  Mod Pathol       Date:  2008-05-23       Impact factor: 7.842

9.  Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.

Authors:  Ardian Latifi; Rodney B Luwor; Maree Bilandzic; Simon Nazaretian; Kaye Stenvers; Jan Pyman; Hongjian Zhu; Erik W Thompson; Michael A Quinn; Jock K Findlay; Nuzhat Ahmed
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

Review 10.  Ovarian cancer: can proteomics give new insights for therapy and diagnosis?

Authors:  Angela Toss; Elisabetta De Matteis; Elena Rossi; Lara Della Casa; Anna Iannone; Massimo Federico; Laura Cortesi
Journal:  Int J Mol Sci       Date:  2013-04-15       Impact factor: 5.923

View more
  8 in total

1.  Tubulin Beta 2C Chain (TBB2C), a Potential Marker of Ovarian Cancer, an Insight from Ovarian Cancer Proteome Profile.

Authors:  Shahzadi Noreen; Safa Akhtar; Tahira Batool; Qurratulann Afza Gardner; Muhammad Waheed Akhtar
Journal:  ACS Omega       Date:  2021-04-13

2.  Identification of blood biomarkers in glioblastoma by SWATH mass spectrometry and quantitative targeted absolute proteomics.

Authors:  Eisuke Miyauchi; Takuya Furuta; Sumio Ohtsuki; Masanori Tachikawa; Yasuo Uchida; Hemragul Sabit; Wataru Obuchi; Tomoko Baba; Michitoshi Watanabe; Tetsuya Terasaki; Mitsutoshi Nakada
Journal:  PLoS One       Date:  2018-03-07       Impact factor: 3.240

3.  Role of lncRNA-ATB in ovarian cancer and its mechanisms of action.

Authors:  Donglan Yuan; Xiaofang Zhang; Yinling Zhao; Hua Qian; Hezhu Wang; Cuiqin He; Xia Liu; Ting Guo; Mei Lin; Hong Yu; Jun Ye
Journal:  Exp Ther Med       Date:  2019-12-04       Impact factor: 2.447

4.  Construction and validation of a prognostic risk model for breast cancer based on protein expression.

Authors:  Bo Huang; Xujun Zhang; Qingyi Cao; Jianing Chen; Chenhong Lin; Tianxin Xiang; Ping Zeng
Journal:  BMC Med Genomics       Date:  2022-07-04       Impact factor: 3.622

5.  Plasma Gelsolin Reinforces the Diagnostic Value of FGF-21 and GDF-15 for Mitochondrial Disorders.

Authors:  Ana Peñas; Miguel Fernández-De la Torre; Sara Laine-Menéndez; David Lora; María Illescas; Alberto García-Bartolomé; Montserrat Morales-Conejo; Joaquín Arenas; Miguel A Martín; María Morán; Cristina Domínguez-González; Cristina Ugalde
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

6.  Platelet protein biomarker panel for ovarian cancer diagnosis.

Authors:  Marta Lomnytska; Rui Pinto; Susanne Becker; Ulla Engström; Sonja Gustafsson; Christina Björklund; Markus Templin; Jan Bergstrand; Lei Xu; Jerker Widengren; Elisabeth Epstein; Bo Franzén; Gert Auer
Journal:  Biomark Res       Date:  2018-01-12

Review 7.  Plasma Gelsolin: Indicator of Inflammation and Its Potential as a Diagnostic Tool and Therapeutic Target.

Authors:  Ewelina Piktel; Ilya Levental; Bonita Durnaś; Paul A Janmey; Robert Bucki
Journal:  Int J Mol Sci       Date:  2018-08-25       Impact factor: 5.923

8.  Characterization of ovarian cancer cells and tissues by Fourier transform infrared spectroscopy.

Authors:  Lei Li; Xiaoning Bi; Hengzi Sun; Simiao Liu; Mei Yu; Ying Zhang; Shifu Weng; Limin Yang; Yanan Bao; Jinguang Wu; Yizhuang Xu; Keng Shen
Journal:  J Ovarian Res       Date:  2018-08-02       Impact factor: 4.234

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.